Icecure Medical is trading at $6.45 (19.4%) up today, extending a sharp rally driven by recent FDA-related adoption news and strategic financing.
- The move follows June 17 announcements regarding U.S. ProSense adoption after FDA breast-cancer authorization and a forecast for record 2025 sales.
- Speculative interest is being fueled by a $5.5 million private placement priced at a premium with a healthcare institutional investor in this low-float name.